Clinical Trial Search

Primary: Postoperative Pain on a Visual Analogue Pain Scale at One Hour Postoperatively — 4.04; 5.09; 4.4 units on a scale

Primary: Anterior Chamber Cell Grade — 38; 7 Participants

Primary: Anterior Chamber Cell Grade — 67; 18 Participants

Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635

Primary: Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment — -0.126; 0.026 TBR

Primary: Medical Record Review and Treatment Utilization Form — 19; 17 Participants — p=.6469

Primary: System Usability Scale (SUS) — 79.6 score on a scale

Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03

Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004

Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci

Primary: Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6 — 2.6; 0.8 mmHg (millimeters of mercury)

Primary: Feasibility, Assessed by Examining Number of Participants Accrued — 20 Participants

Primary: Change From Pre-Treatment in Average Pain Intensity on a 0-10 Numerical Rating Scale Immediately Following End of Treatment (Post-Treatment) — -.57; -.61; -.85 score on…

Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants

Primary: Change in Quantitative Pain Testing Following Active TMS Compared to Baseline — 1.4; .3 Change from Baseline (degrees C) — p=.83